Table 4.
Model | Compound/Component | Effect | Reference |
---|---|---|---|
In vitro | |||
HL60 NB4 | EGCG 0–40 µmol/L (24–36h) ATRA—1 µmol/L |
Induction of neutrophil differentiation—↑ CD11b surface expression EGCG + ATRA—↑ CD11b and CD15 expression; ↑ CEBPE, CSF3R and DAPK2; and ↓ of undifferentiated promyelocytes and myelocytes |
[16] |
NB4 NB4 R1 NB4 R2 |
Catechins 100–200 µM (12–24 h) |
Induction of PML/RARα degradation | [33] |
NB4 | EGCG 0–30 µM (72 h) ATRA—10 µM |
Induction of PML-RARα degradation by inhibition of Pin1 (↓) | [107] |
HL-60 NB4 | EGCG 0–100 µM (24–72 h) ATRA—10 µM |
Induction of granulocytic maturation—morphological changes and ↑ NBT reduction ability; and degradation of PML/RARα (↓) and HDAC1 (↓) | [106] |
HL60 NB4 THP-1 | EGCG 5–40 µM (48 h) ATRA 1 µM/mL |
Induction of PML/RARα degradation (↓) and restored PML (↑) and PTEN (↑) function EGCG + ATRA—↑ PTEN, CD11b, CEBPE |
[108] |
NB4 | EGCG 12.5–20 µg/mL ATRA—1 µM |
Induction of neutrophil differentiation—↑ of CD11b, CD14, CD15 and CD66 surface expression EGCG + ATRA—↑ CD15 expression |
[7] |
In vivo—Xenograft and systemics model | |||
CTSG-PML-RARA transgenic mice cells in C57BL/6J mice |
EGCG 12.50 mg/kg/d intraperitoneally for 21 days ATRA—5 mg |
Induction of PML-RARα degradation in bone marrow cells and ↓ of spleen weight | [107] |
hCG-PML/RAR transgenic mice cells in NOD. CB17-Prkdcscid/J mice |
EGCG 25 mg/kg/d intraperitoneally, for 5 days |
Induction of differentiation—↓ immature cells and undifferentiated promyelocytes in the bone marrow, ↑ mature myeloid cells, ↓ PIN1 and its substrates—cyclin D, NFκB, c-Myc and AKT and ↑ ROS; ↓ of spleen weight | [7] |